RCS - Alia Therapeutics - Alia Therapeutics names Letizia Goretti as CEO

Johnson & JohnsonAnnouncement

05/05/2023 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230505:nRSE4970Ya&default-theme=true

RNS Number : 4970Y  Alia Therapeutics  05 May 2023

Alia Therapeutics names Letizia Goretti as Chief Executive Officer

MILAN, ITALY / ACCESSWIRE / May 5, 2023 / Alia Therapeutics
(https://pr.report/MbmLyNof) , a Trento-based start-up specializing in
innovative treatments for rare genetic diseases through next-generation gene
editing technology, announced the appointment of Letizia Goretti as Chief
Executive Officer (CEO) and Board Director, effective immediately.

Related Image
(https://www.accesswire.com/users/newswire/images/753018/alia%20logo.png)

Letizia, who is joining Alia from Johnson & Johnson, has more than 25
years of international experience in life sciences. She brings a broad
background in strategic, operational, R&D, and commercial activities
across the sector, and a track record of building strong partnerships and
delivering sustainable value to stakeholders and patients.

In her previous role as Senior Director, Transactions and Alliances at the
Johnson & Johnson Innovation Centre in London, she led strategic
partnering efforts with academia, entrepreneurs, industries, governmental
organizations, and charities, focusing on the development and adoption of
genomics and digital capabilities for discovery and development.

"Letizia's appointment as CEO marks an important step forward for Alia," said
Paola Pozzi, a Partner at Sofinnova Partners. "Her all-round experience and
leadership skills, combined with her drive to create value through innovation,
will be a great catalyst to accelerate Alia's growth."

"I am fascinated by the opportunity to work with a team of cutting-edge
scientists on a quest to develop its innovative platform for CRISPR-based
medicine," Letizia said. "We are enabling novel gene editing strategies
designed to overcome current limitations and bring more therapies to patients
with underserved and currently untreatable diseases and conditions."

"Our Board of Directors is thrilled to appoint a leader like Letizia," said
Silvano Spinelli, Chairman of the Board of Directors. "With her broad
background and track record of value creation, she is well positioned to guide
Alia into a bright future."

Letizia holds a M.Sc. in Chemistry from the University of Perugia. She started
her career at Bristol-Myers Squibb in Italy before moving to The Janssen
Pharmaceutical Companies, a unit of Johnson & Johnson, where she held
several roles with increasing responsibilities and international scope in
business development, CMC development, commercial life cycle management and
global new product launches.

In April, Alia announced a €4.4 million seed financing extension led by
Sofinnova Partners through the Sofinnova Telethon Fund. Other investors
included Indaco Bio and a group of Italian investors brought together by Banor
SIM and Banca Profilo.

About Alia Therapeutics

Alia Therapeutics is an Italian biotech start-up whose mission is to develop
innovative treatments for incurable genetic diseases using gene editing
technology. The company was founded in October 2018 by Anna Cereseto and a
group of researchers from CIBIO, the biotech department of the University of
Trento, who discovered the core CRISPR technologies exploited by the start-up.
Read more at aliatherapeutics.com (https://pr.report/8RNAvY3d) .

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life
sciences, specializing in healthcare and sustainability. Based in Paris,
London and Milan, the firm brings together a team of professionals from all
over the world with strong scientific, medical and business expertise.
Sofinnova Partners is a hands-on company builder across the entire value chain
of life sciences investments, from seed to later-stage. The firm actively
partners with ambitious entrepreneurs as a lead or cornerstone investor to
develop transformative innovations that have the potential to positively
impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply established venture capital
firm in Europe, with 50 years of experience backing over 500 companies and
creating market leaders around the globe. Today, Sofinnova Partners has over
€2.5 billion under management. For more information, please
visit: sofinnovapartners.com (https://pr.report/be5VwYCP) .

For more information about Sofinnova Telethon,
visit https://sofinnovapartners.com/strategy/telethon
(https://pr.report/4FQNHwbA)

Contact

Letizia Goretti

CEO, Alia Therapeutics
info@aliatx.com (mailto:info@aliatx.com)
Tel: +39 0461 283917

SOURCE: Alia Therapeutics

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSAFWLEDSEDI